Momentum Builds for ALX Oncology and Delta Apparel
- October 03rd, 2023
- 536 views
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive gastric cancer, on Tuesday, October 3.
$ALXO was trading at $5.90, marking a substantial increase of $1.09 (+22.66%) during the extended session.
In unrelated news, Delta Apparel, Inc. (NYSE American: DLA) revealed that it has received an unsolicited offer for its Salt Life business unit. The company's Board of Directors has enlisted Baird as its financial advisor for this development. It's important to note that the timing, terms, or structure of any potential transaction, as well as the likelihood of a transaction occurring, remain uncertain.
In after-hours, $DLA was trading at $7.89, up $1.30 (+19.73%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login